NAA16

Across TCGA pan-cancer cohorts, NAA16 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NAA16 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NAA16 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NAA16 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where NAA16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.654	0.329	.008	14	view →
LSCC	DFS	Tertile	All	0.852	0.649	.027	9	view →
HNSC	DFS	Median	II,III,IV	0.766	0.553	.012	7	view →
CCRCC	OS	Median	III,IV	1.000	0.842	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NAA16–PDAC (OS)

Open the PDAC breakdown →